Thymosin β4 stabilizes hypoxia induced brain microvascular endothelial cell dysfunction through S1PR1 dependent mechanisms.
This study investigated how Thymosin β4 (Tβ4), a 43-amino-acid secreted peptide, may protect against hypoxia-induced blood-brain barrier (BBB) disruption using human brain microvascular endothelial cells (hBMVECs) as an in vitro model. The researchers exposed hBMVECs to hypoxic conditions to simulate aspects of ischemic injury and traumatic brain injury (TBI), then examined whether Tβ4 pretreatment could reverse resulting damage. They measured gene expression of tight junction proteins, Sphingosine 1-phosphate receptor 1 (S1PR1), endothelial cell permeability, and tight junction dynamics. The study found that Tβ4 pretreatment appeared to reverse hypoxia-induced impairment of BBB components, and identified S1PR1 as a potential mechanistic target. Notably, when S1PR1 was pharmacologically inhibited, Tβ4 lost its protective effect, suggesting S1PR1 signaling is required for Tβ4's action. The authors conclude that S1PR1 pathway modulation is central to hypoxia-induced BBB pathophysiology and propose Tβ4 as a candidate therapeutic agent warranting further investigation. Key limitations include the exclusive use of cell culture models, absence of animal or human data, and lack of in vivo validation of the proposed mechanism.
Why this grade: All experiments were conducted exclusively in human brain microvascular endothelial cell cultures with no animal models or human subjects, limiting conclusions to cellular mechanisms only.
Acute ischemic injury causes impairment of blood brain barrier (BBB) permeability and is considered as secondary insult in the brain after traumatic brain injury (TBI). The mechanisms underlying these events are incomprehensible and therefore therapeutic opportunities are limited. Although drugs have been showing some promise in TBI outcome, the restoration of BBB damage remain elusive. Thymosin β4 (Tβ4) is a secreted 43 amino acid peptide showed beneficial outcome in cerebral ischemia or TBI, however, it's role in hypoxia-induced BBB damage remains elusive. We hypothesize that Tβ4 protect hypoxia-induced BBB disruption via Sphingosine 1-phosphate receptor 1 (S1PR1) modulation. In the current study, we investigated the beneficial effects of Tβ4 in hypoxia induced gene expression of several tight junction proteins, S1PR1, endothelial cell permeability and tight junction dynamics in human brain microvascular endothelial cells (hBMVECs), one of the important cell types in the BBB integrity. The data suggests that pretreatment with Tβ4 reversed the hypoxia-induced damage of BBB components in hBMVECs. Furthermore, results identify S1PR1, a possible target for Tβ4. Inhibition of S1PR1 showed that Tβ4 failed to offer protection. Together, data provided evidence that S1PR1 is pivotal and Tβ4 can serve as a protective agent in BBB integrity and may offer a promising therapeutic target. In conclusion, we propose that depletion of S1PR1signaling is vital in hypoxia-induced BBB pathophysiology and Tβ4 may be tested as a potential treatment modality and warrant further investigation.
Educational summary of published research — not medical advice. License: cc by. Full text is shown only where licensing permits.